Cello Health plc (AIM:CLL) acquired trade and assets of Innovative Science Solutions, LLP for $10.5 million on August 15, 2019. Initial consideration of $6.4 million will be paid in cash. In addition, deferred consideration of up to $4.1 million will be payable in four tranches, each dependent on financial performance over the periods from August 1, 2019 to July 31, 2024. This deferred consideration will be paid in a minimum of 80% cash, with the balance to be satisfied through the issue of new ordinary shares in Cello Health. Initial cash consideration will be funded from Cello Health's existing cash and debt facilities. Mark Connelly and Harry Hargreaves of Harry Hargreaves of acted as financial advisors for Cello Health. Cello Health plc (AIM:CLL) completed the acquisition of trade and assets of Innovative Science Solutions, LLP on August 15, 2019.